Most severe DENV-2 infections in humans occur during secondary infections, in which antibody-dependent enhancement (ADE) mediated by non-neutralizing heterotypic anti-DENV antibodies plays a central role in pathogenesis by promoting hyper-infection of mononuclear phagocytes through FCγ receptors (CD32, CD16). The gene discussed is FCGR3A; the disease is infection.